PharmaBlock Sciences Nanjing Inc
SZSE:300725

Watchlist Manager
PharmaBlock Sciences Nanjing Inc Logo
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Watchlist
Price: 35.78 CNY 1.07%
Market Cap: 7.1B CNY
Have any thoughts about
PharmaBlock Sciences Nanjing Inc?
Write Note

PharmaBlock Sciences Nanjing Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PharmaBlock Sciences Nanjing Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
PharmaBlock Sciences Nanjing Inc
SZSE:300725
Gross Profit
ÂĄ601.5m
CAGR 3-Years
2%
CAGR 5-Years
13%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Gross Profit
ÂĄ9.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Gross Profit
ÂĄ4.8B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Gross Profit
ÂĄ22.1B
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Gross Profit
ÂĄ10.5B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Gross Profit
ÂĄ319.6m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PharmaBlock Sciences Nanjing Inc
Glance View

Market Cap
7.1B CNY
Industry
Pharmaceuticals

PharmaBlock Sciences (Nanjing), Inc. engages in the innovation of chemistry products and services throughout the pharmaceutical research and development process. The company is headquartered in Nanjing, Jiangsu and currently employs 1,735 full-time employees. The company went IPO on 2017-11-10. The firm's primary products include aromatic heterocyclic drug molecular building blocks, common saturated alicyclic drug molecular building blocks, four-membered ring drug molecular building blocks and special saturated ring drug molecular building blocks. The firm is also involved in development, production and sales of pharmaceutical intermediates, and provides technical services related to the development and process production of pharmaceutical molecular building blocks.

Intrinsic Value
54.21 CNY
Undervaluation 34%
Intrinsic Value
Price

See Also

What is PharmaBlock Sciences Nanjing Inc's Gross Profit?
Gross Profit
601.5m CNY

Based on the financial report for Sep 30, 2024, PharmaBlock Sciences Nanjing Inc's Gross Profit amounts to 601.5m CNY.

What is PharmaBlock Sciences Nanjing Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
13%

Over the last year, the Gross Profit growth was -15%. The average annual Gross Profit growth rates for PharmaBlock Sciences Nanjing Inc have been 2% over the past three years , 13% over the past five years .

Back to Top